Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: A phase III, randomized controlled trial (ESTEEM 2)

British Journal of Dermatology

Volumn 173, Issue 6, 2015, Pages 1387-1399

  Paul, C ^a   Cather, J ^b   Gooderham, M ^c   Poulin, Y ^d   Mrowietz, U ^e   Ferrandiz, C ^f,g   Crowley, J ^h   Hu, C ⁱ   Stevens, R M ⁱ   Shah, K ⁱ   Day, R M ⁱ   Girolomoni, G ^j   Gottlieb, A B ^k  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b Modern Research Associates   (United States)

^c Skin Centre for Dermatology   (Canada)

^d Centre de Recherche Dermatologique du Québec Métropolitain   (Canada)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^g UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^h Bakersfield Dermatology   (United States)

ⁱ CELGENE CORPORATION   (United States)

^j UNIVERSITY OF VERONA   (Italy)

^k TUFTS MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

APREMILAST; PLACEBO; NONSTEROID ANTIINFLAMMATORY AGENT; THALIDOMIDE;

ADULT; ARTICLE; BACKACHE; CONTROLLED STUDY; DERMATOLOGY LIFE QUALITY INDEX; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; OPPORTUNISTIC INFECTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK ASSESSMENT; TENSION HEADACHE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; ANALOGS AND DERIVATIVES; ANALYSIS OF VARIANCE; CHRONIC DISEASE; CLINICAL TRIAL; DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHRONIC DISEASE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84983095431     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.14164     Document Type: Article

References (25)

1. Reich K,. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol 2012; 26 (Suppl. 2): 3-11.
2. Parisi R, Symmons DP, Griffiths CE, et al,. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133: 377-85.
3. Coimbra S, Figueiredo A, Castro E, et al,. The roles of cells and cytokines in the pathogenesis of psoriasis. Int J Dermatol 2012; 51: 389-95.
4. Benham H, Norris P, Goodall J, et al,. Th17 and Th22 cells in psoriatic arthritis and psoriasis. Arthritis Res Ther 2013; 15: R136.
5. Arican O, Aral M, Sasmaz S, Ciragil P,. Serum levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005; 2005: 273-9.
6. Coimbra S, Oliveira H, Reis F, et al,. Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor-α levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy. Br J Dermatol 2010; 163: 1282-90.
7. Tonel G, Conrad C, Laggner U, et al,. Cutting edge: a critical functional role for IL-23 in psoriasis. J Immunol 2010; 185: 5688-91.
8. Yawalkar N, Tscharner GG, Hunger RE, Hassan AS,. Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis. J Dermatol Sci 2009; 54: 99-105.
9. Boniface K, Guignouard E, Pedretti N, et al,. A role for T cell-derived interleukin 22 in psoriatic skin inflammation. Clin Exp Immunol 2007; 150: 407-15.
10. Schafer P,. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol 2012; 83: 1583-90.
11. Schett G, Sloan VS, Stevens RM, Schafer P,. Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases. Ther Adv Musculoskelet Dis 2010; 2: 271-8.
12. Schafer PH, Parton A, Gandhi AK, et al,. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 2010; 159: 842-55.
13. Otezla [package insert]. Summit, NJ: Celgene Corporation, September 2014.
14. Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al,. Treatment of psoriatic arthritis in a phase 3 randomized, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 2014; 73: 1020-6.
15. Reich A, Medrek K, Stander S, et al,. Determination of minimum clinically important difference (MCID) of visual analogue scale (VAS): in which direction should we proceed? Acta Derm Venereol 2013; 93: 609-10 [Abstr. IL26].
16. Reich K, Papp K, Leonardi C, et al,. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: 16-week results of a phase 3, randomized, controlled trial (ESTEEM 1). Presented at the Annual Meeting of the American Academy of Dermatology, Miami, FL, U.S.A., 1-5 March 2013.
17. Papp K, Griffiths C, Leonardi C, et al,. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: results from the randomized treatment withdrawal phase of a phase 3, randomized, controlled trial (ESTEEM 1). J Am Acad Dermatol 2014; 70 (Suppl. 1): AB164. [Abstr. P83587].
18. Reich K, Soung J, Gooderham M, et al,. Efficacy and safety of apremilast or etanercept compared with placebo in patients with moderate to severe psoriasis. Presented at the Annual Meeting of the American Academy of Dermatology, San Francisco, CA, U.S.A., 20-24 March 2015 [Abstr. F010].
19. Papp K, Reich K, Leonardi CL, et al,. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM 1]). J Am Acad Dermatol 2015; 73: 37-49.
20. Papp K, Cather J, Rosoph L, et al,. The efficacy of apremilast, a phosphodiesterase-4 inhibitor, in the treatment of moderate to severe psoriasis: results of a phase 2 randomised study. Lancet 2012; 380: 738-46.
21. Pathirana D, Ormerod AD, Saiag P, et al,. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 (Suppl. 2): 1-70.
22. Mrowietz U, Kragballe K, Reich K, et al,. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1-10.
23. Lebwohl MG, Bachelez H, Barker J, et al,. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol 2014; 70: 871-81.
24. Armstrong AW, Robertson AD, Wu J, et al,. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol 2013; 149: 1180-5.
25. van de Kerkhof PCM, Reich K, Kavanaugh A, et al,. Physician perspectives in the managment of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey. J Eur Acad Dermatol Venereol 2015; 29: 2002-10. (in press)